Comparative Evaluation of GeneXpert MTB/RIF Ultra and GeneXpert MTB/RIF for Detecting Tuberculosis and Identifying Rifampicin Resistance in Pars Plana Vitrectomy Samples of Patients with Ocular Tuberculosis
BACKGROUND: Xpert MTB/RIF Ultra (Ultra) was evaluated for the first time on Ocular tuberculosis (OTB) samples and compared with Xpert.
METHODS: Seventy five vitreous fluid samples (3 confirmed OTB, 47 clinically suspected OTB, and 25 controls) were subjected to Ultra, Xpert and Multiplex-PCR and compared against culture, composite reference standard (CRS), and gene sequencing.
RESULTS: The sensitivity of Ultra was 50% in diagnosing OTB (100% against culture and 46.8% against CRS). The overall sensitivity of Xpert and MPCR was 16% and 72%, respectively. Xpert missed three culture-positive cases and MPCR detected additional 11. Ultra and Xpert missed two and four cases of RifR, respectively. A total of 13(59%) cases were reported 'trace' by Ultra in which RifR could not be evaluated.
CONCLUSION: Ultra outperformed Xpert in diagnosing OTB. The advantage of Ultra's simultaneous RifR detection is lost since the trace bacterial loads in the specimens cause indeterminate results of RifR testing.Abbreviations: OTB: Ocular tuberculosis; Ultra: Xpert MTB/RIF Ultra; Xpert: Xpert MTB/RIF, MPCR: multiplex polymerase chain reaction; NAATs: Nucleic acid amplification tests; MLAMP: multitargeted loop-mediated isothermal amplification; PPV: positive predictive value; NPV: negative predictive value; EPTB: extrapulmonary tuberculosis; VF: vitreous fluid; DNA: deoxyribonucleic acid; ATT: antitubercular therapy; RifR: Rifampicin resistance; RifS: Rifampicin susceptible; RifI: Rifampicin indeterminate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Ocular immunology and inflammation - 31(2023), 5 vom: 01. Juli, Seite 914-920 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Kusum [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibiotics, Antitubercular |
|---|
| Anmerkungen: |
Date Completed 29.06.2023 Date Revised 29.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09273948.2022.2064880 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339721200 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339721200 | ||
| 003 | DE-627 | ||
| 005 | 20231226003529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09273948.2022.2064880 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339721200 | ||
| 035 | |a (NLM)35442853 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Kusum |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative Evaluation of GeneXpert MTB/RIF Ultra and GeneXpert MTB/RIF for Detecting Tuberculosis and Identifying Rifampicin Resistance in Pars Plana Vitrectomy Samples of Patients with Ocular Tuberculosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2023 | ||
| 500 | |a Date Revised 29.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Xpert MTB/RIF Ultra (Ultra) was evaluated for the first time on Ocular tuberculosis (OTB) samples and compared with Xpert | ||
| 520 | |a METHODS: Seventy five vitreous fluid samples (3 confirmed OTB, 47 clinically suspected OTB, and 25 controls) were subjected to Ultra, Xpert and Multiplex-PCR and compared against culture, composite reference standard (CRS), and gene sequencing | ||
| 520 | |a RESULTS: The sensitivity of Ultra was 50% in diagnosing OTB (100% against culture and 46.8% against CRS). The overall sensitivity of Xpert and MPCR was 16% and 72%, respectively. Xpert missed three culture-positive cases and MPCR detected additional 11. Ultra and Xpert missed two and four cases of RifR, respectively. A total of 13(59%) cases were reported 'trace' by Ultra in which RifR could not be evaluated | ||
| 520 | |a CONCLUSION: Ultra outperformed Xpert in diagnosing OTB. The advantage of Ultra's simultaneous RifR detection is lost since the trace bacterial loads in the specimens cause indeterminate results of RifR testing.Abbreviations: OTB: Ocular tuberculosis; Ultra: Xpert MTB/RIF Ultra; Xpert: Xpert MTB/RIF, MPCR: multiplex polymerase chain reaction; NAATs: Nucleic acid amplification tests; MLAMP: multitargeted loop-mediated isothermal amplification; PPV: positive predictive value; NPV: negative predictive value; EPTB: extrapulmonary tuberculosis; VF: vitreous fluid; DNA: deoxyribonucleic acid; ATT: antitubercular therapy; RifR: Rifampicin resistance; RifS: Rifampicin susceptible; RifI: Rifampicin indeterminate | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IS1081 | |
| 650 | 4 | |a IS6110 | |
| 650 | 4 | |a MDR-TB | |
| 650 | 4 | |a molecular diagnosis | |
| 650 | 4 | |a tuberculous uveitis | |
| 650 | 7 | |a Antibiotics, Antitubercular |2 NLM | |
| 650 | 7 | |a Rifampin |2 NLM | |
| 650 | 7 | |a VJT6J7R4TR |2 NLM | |
| 700 | 1 | |a Sharma, Megha |e verfasserin |4 aut | |
| 700 | 1 | |a Ayyadurai, Nikitha |e verfasserin |4 aut | |
| 700 | 1 | |a Dogra, Mohit |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Aman |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Vishali |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Ramandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Amod |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d 1993 |g 31(2023), 5 vom: 01. Juli, Seite 914-920 |w (DE-627)NLM091014069 |x 1744-5078 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:5 |g day:01 |g month:07 |g pages:914-920 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2022.2064880 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 5 |b 01 |c 07 |h 914-920 | ||